Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease

Clin Infect Dis. 2017 Sep 1;65(5):864-866. doi: 10.1093/cid/cix441.

Abstract

Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

Keywords: HCV; LDV/SOF; hepatitis C infection; ledipasvir; sickle cell disease.

MeSH terms

  • Adult
  • Anemia, Sickle Cell / complications*
  • Antiviral Agents* / administration & dosage
  • Antiviral Agents* / adverse effects
  • Antiviral Agents* / therapeutic use
  • Benzimidazoles* / administration & dosage
  • Benzimidazoles* / adverse effects
  • Benzimidazoles* / therapeutic use
  • Drug Combinations
  • Female
  • Fluorenes* / administration & dosage
  • Fluorenes* / adverse effects
  • Fluorenes* / therapeutic use
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Sofosbuvir* / administration & dosage
  • Sofosbuvir* / adverse effects
  • Sofosbuvir* / therapeutic use
  • Young Adult

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Drug Combinations
  • Fluorenes
  • ledipasvir
  • Sofosbuvir